Facilitating Clinical Implementation of Pharmacogenomics
Open accessThe DOI matches its Crossref record.
Abstract
Variability in drug response can be explained, in part, by genetic differences among patients.A clear role in drug toxicity and efficacy has been established for some gene-drug combinations, yet implementation of pharmacogenomic tests in clinical practice lags behind this knowledge.The evidence-adoption gap for many pharmacogenomic tests can be addressed in the short term through the development of consensus-based practice guidelines and clinician education.For genetic variants associated with severe drug toxicities, there is a strong impetus for adoption.An example is the HLA-B*15:02 variant, associated with the potentially lethal Stevens-Johnson syndrome in Asian patients treated with carbamazepine. 1 Another example is the poor metabolizers of cytochrome p450 2D6 substrates that represent a range of risk when exposed to specific medications.The death of a child treated with fluoxetine illustrates the importance of identifying patients with impaired metabolism as well as the ethical dilemma of knowingly exposing patients with minimal metabolic capacity to substrates that require a specific enzyme for clearance.2 The adoption of testing for genetic variants that have a more modest effect on drug response or risk of adverse events has been more variable.In oncology, somatic mutation or expression tests for specific drug targets in tumors (eg, EGFR, ERBB2) can provide a clear indication for treatment efficacy, and rates of adoption have been relatively high.However, the current evidence for other pharmacogenomic tests for efficacy determination is less clear.For example, patients of European ancestry who carry the higher-activity allele of a serotonin transporter gene variant have a modest increased probability of responding to serotonin reuptake inhibitors.3 The decision to use testing to increase the probability of a good response must be weighed against other issues, such as the efficacy and cost of ©2011 American Medical Association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580
Self-citationThe social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392
“…early diagnosis, and improved education for clinicians and patients, when combined with more consistent processes for regulatory requirements and reimbursements of new therapeutics and diagnostics, will help to reduce the burden of TRS in the USA (Mrazek and Lerman, 2011; Wilke and Dolan, 2011).”
BackgroundYan, T., Wang, L., Kuang, W., Xu, J., Li, S., Chen, J., & Yang, Y. (2014) · Asia-Pacific Psychiatry · doi:10.1111/appy.12148 · Cited by 46
“Furthermore, common genetic variants in MDD patients might influence the choice and effectiveness of antidepressant treatment (Kim et al., 2006; Perroud et al., 2009; Mrazek and Lerman, 2011).”
Background
Metadata
- Authors
- Mrazek, D. A., & Lerman, C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-07-20
- Volume
- 306
- Issue
- 3
- Pages
- 304-5
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2063395862
- Cited by
- 64
- References
- 0
- FWCI
- 10.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Facilitating Clinical Implementation of Pharmacogenomics. https://app.cochat.ai/papers/10.1001/jama.2011.1010
- The paper
- Mrazek, D. A., & Lerman, C. (2011). Facilitating Clinical Implementation of Pharmacogenomics. JAMA. https://doi.org/10.1001/jama.2011.1010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.